Comparison of three TaqMan Real-Time Reverse Transcription-PCR assays in detecting SARS-CoV-2

Running title: Comparison of 3 qRT-PCR assays detecting SARS-CoV-2

Yan Xiao ^{1#}, Zhen Li ^{2#}, Xinming Wang ¹, Yingying Wang ¹, Ying Wang ¹, Geng Wang ¹, Lili Ren ^{1, 3*}, Jianguo Li ^{2*}

¹ National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, P. R. China.

² Institutes of Biomedical Sciences, Shanxi University, Taiyuan, 030006, P. R. China.

³ Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, P. R. China.

[#]These authors contributed equally to this work

*Corresponding author

Dr. Jianguo Li

No. 92 Wucheng Road, Xiaodian District, Taiyuan 030006, P.R. China

Email: lijg@sxu.edu.cn

Tel/Fax: 86-351-7018958

Co-corresponding author:

Dr Lili Ren

No.9 Dong Dan San Tiao, Dongcheng District,

Beijing 100730, P. R. China

E-mail: renliliipb@163.com

Tel/Fax: 86-10-67855226

Abstract word count: 246

Text word count: 2037

34 Abstract

35 Quick and accurate detection of SARS-CoV-2 is critical for COVID-19 control.
 36 Dozens of real-time reverse transcription PCR (qRT-PCR) assays have been
 37 developed to meet the urgent need of COVID-19 control. However, methodological
 38 comparisons among the developed qRT-PCR assays are limited. In the present study,
 39 we evaluated the sensitivity, specificity, amplification efficiency, and linear detection
 40 ranges of three qRT-PCR assays, including the assays developed by our group
 41 (IPBCAMS), and the assays recommended by WHO and China CDC (CCDC). The
 42 three qRT-PCR assays exhibited similar sensitivities, with the limit of detection (LOD)
 43 at about 10 copies per reaction (except the ORF 1b gene assay in CCDC assays with a
 44 LOD at about 100 copies per reaction). No cross reaction with other respiratory
 45 viruses were observed in all of the three qRT-PCR assays. Wide linear detection
 46 ranges from 10^6 to 10^1 copies per reaction and acceptable reproducibility were
 47 obtained. By using 25 clinical specimens, the N gene assay of IPBCAMS assays and
 48 CCDC assays performed better (with detection rates of 92% and 100%, respectively)
 49 than that of the WHO assays (with a detection rate of 60%), and the ORF 1b gene
 50 assay in IPBCAMS assays performed better (with a detection rate of 64%) than those
 51 of the WHO assays and the CCDC assays (with detection rates of 48% and 20%,
 52 respectively). In conclusion, the N gene assays of CCDC assays and IPBCAMS
 53 assays and the ORF 1b gene assay of IPBCAMS assays were recommended for
 54 qRT-PCR screening of SARS-CoV-2.

55 **Key words:** SARS-CoV-2; qRT-PCR; methodological evaluation; Limit of Detection;
 56 reproductivity, clinical performance

57 **Introduction**

58 Since the first detection in late 2019, severe respiratory syndrome CoV-2
 59 (SARS-CoV-2) caused Corona Virus Infectious Disease in 2019 (COVID-19) has
 60 widely spread in the world. By April 11, 2020, more than 1.7 million patients infected
 61 by SARS-CoV-2 has been reported from 185 countries (1). Given the quick increase
 62 in confirmed cases and asymptomatic infections, there are increasing demands in
 63 diagnostic tools for quick and accurate detection of the virus (2, 3). Several real-time
 64 reverse transcription-Polymerase Chain Reaction (qRT-PCR) for the detection of
 65 SARS-COV-2 has been developed to meet the demands, including the assays by this
 66 group (IPBCAMS assays), and the assays by WHO (WHO assays), and the assays by
 67 China CDC (CCDC assays).

68 Because SARS-CoV-2 usually infected the lower respiratory tract, it is not easy to
 69 detect the viral nucleic acids from throat swabs with relatively lower viral load (4).
 70 Thus, qRT-PCR assays with higher sensitivity and better performance in the detection
 71 of SARS-CoV-2 is recommended in aiding the diagnosis of COVID-19 (2). However,
 72 most of the current available qRT-PCR assays were developed for emergency, a
 73 comprehensive methodological comparison among these assays remains unfulfilled.
 74 To comprehensively compare the performance of currently available qRT-PCR assays
 75 for detection of SARS-CoV-2, we evaluated the sensitivity, specificity, amplification
 76 efficiency, and linear detection ranges among IPBCAMS assays, WHO assays and
 77 CCDC assays.

78 **Materials and methods**

79 **Nucleic acid extraction**

80 Nucleic acids were extracted from a volume of 200 µl clinical samples by using
 81 NucliSens easyMag apparatus (bioMe´rieux, MarcyL'Etoile, France) according to the
 82 manufacturer's instructions. A volume of 50 µl total nucleic acid eluate for each
 83 specimen was recovered and transferred into a nuclease-free vial and either tested
 84 immediately or stored at -80°C.

85 **Primers and probes**

86 Sequences of primers and probes for the IPBCAMS assays were recently developed
 87 (5), while those for the WHO assays were obtained from the website of WHO
 88 ([https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef](https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2)
 89 [618c_2](https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2)), and those for the CCDC assays were obtained from the website of China
 90 CDC

91 (http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/W020200309540
92 843062947.pdf) (Table 1). Primers and probes were synthesized by standard
93 phosphoramidite chemistry techniques at Qingke biotechnology Co. Ltd (Beijing,
94 China). TaqMan probes were labeled with the molecule 6-carboxy-fluorescein (FAM)
95 at the 5' end, and with the quencher Blackhole Quencher 1 (BHQ1) at the 3' end.
96 Optimal concentrations of the primers and probes were determined by cross-titration
97 of serial two-fold dilutions of each primer/probe against a constant amount of purified
98 RNA of SARS-CoV-2.

99 **TaqMan real-time RT-PCR assay**

100 The TaqMan real-time RT-PCR assays were performed by using TaqMan Fast Virus
101 1-Step Master Mix (Thermo Fisher Scientific, MA, USA). Each 20 µl reaction mix
102 contained 5 µl of 4×Fast Virus 1-Step Master Mix, 0.2 µl of 50 µM probe, 0.2 µl each
103 of 50 µM forward and reverse primers, 12.4 µl of nuclease-free water, and 2 µl of
104 nucleic acid extract. Amplifications were carried out in 96-well plates by using
105 Bio-Rad instrument (Bio-Rad CFX96, CA, USA). Thermo-cycling conditions are as
106 follows: 15 min at 50°C for reverse transcription, 4 min at 95°C for pre-denaturation,
107 followed by 45 cycles of 15 sec at 95°C and 45 sec at 60°C. Fluorescence
108 measurements were taken at 60°C of each cycle. The threshold cycle (Ct) value was
109 determined by the point at which fluorescence exceeded a threshold limit set at the
110 mean plus 10 standard deviations above the baseline. A result was considered positive if
111 two or more of the SARS-CoV-2 genome targets exhibited positive results ($Ct \leq 35$).
112 A result of $35 \leq Ct \leq 40$ was considered suspected and a repeat test was performed for
113 result confirmation.

114 **Preparation of RNA transcripts**

115 RNA transcripts for N gene and ORF 1b of SARS-CoV-2 were prepared with a
116 plasmid pEasy-T1 (TransGen Biotech, Beijing, China) with T7 promoter before the
117 multiple cloning sites. The plasmids inserted with viral gene regions of N and Orf1b
118 were linearized with the restriction enzyme, BamHI, and transcribed *in-vitro* by using
119 RiboMAXTM Large Scale RNA Production Systems (Promega, WI, USA),
120 respectively. The concentrations of the RNA transcripts were determined by using
121 NanoDrop (Thermo Fisher Scientific, CA, USA).

122 **Results**

Comparison of the sensitivities, reproducibility and linear detection ranges of the three qRT-PCR assays.

To determine the sensitivity of the three qRT-PCR assays, we measured the limit of detection (LOD) for each assay by using RNA transcript of the corresponding gene in ten-fold dilution as template (RNA transcript alone). A LOD of 10 genomic copies per reaction was observed for both the N gene assay and the ORF 1b gene assay of all the three qRT-PCR assays, although the Ct values for N gene assay of WHO assays and ORF 1b gene assay of CCDC assays were higher than 35 cycles (Table 2).

The linear detection ranges of the three qRT-PCR assays were determined by using a ten-fold dilution of the RNA transcript as template. It showed that the Ct values increased with the RNA transcript from 10^6 to 10^1 copies in the reaction in all of the three qRT-PCR assays (Table 2). Strong linear correlations were observed between Ct values and quantity of RNA transcripts with $r^2=0.9926$, 0.9750 , 0.9987 in the N gene assay, and $r^2=0.9953$, 0.9897 , 0.9941 in the ORF 1b assay of IPBCAMS assays, WHO assays, and CCDC assays, respectively. These results suggested that all of the three qRT-PCR assays exhibited linear detection ranges from 10^6 to 10^1 copies per reaction, while the WHO assays showed lower coefficient of linear correlation.

The reproducibility of the three qRT-PCR assays was assessed by measuring coefficient of variation (CV) of mean Ct values in the intra- and inter- assay. For the N gene assay, the CVs of mean Ct values from 10^6 to 10^1 copies of RNA transcript per reaction were 0.20%-1.33%, 0.46%-5.09%, 0.27%-1.97% in intra-assay, and 1.06%-2.45%, 0.96%-7.59%, 1.00%-5.51% in inter-assay of IPBCAMS assay, WHO assay, and CCDC assay, respectively. For the ORF 1b gene assay, the CVs of mean Ct values were 0.26%-4.45%, 0.29%-1.76%, 0.71%-6.52% in intra-assay, and 2.17%-5.12%, 0.30-1.57%, 2.63%-4.34% in inter-assay of IPBCAMS assays, WHO assays, and CCDC assays, respectively.

Because co-infections of respiratory viruses are common, we prepared a (v:v=1:1) mixture of the RNA transcript and a pooled total nucleic acid extract from respiratory specimens (RNA transcript + other extract) as template, to evaluate the effect of co-existed viral nucleic acids on the performance of the assays. No effect of the co-existed other viral nucleic acids on the LOD and the linear detection range was observed, although higher Ct values were generated than those of RNA transcript alone as template in all of the three qRT-PCR assays. However, the co-existed other viral nucleic acids put some effect on the efficiencies of the three qRT-PCR assays.

For the N gene assays, the efficiencies were moved from 105.82%, 107.23%, 102.21% to 110.17%, 124.32%, 119.43% in IPBCAMS assays, WHO assays, CCDC assays, respectively. For the ORF 1b assays, the efficiencies were moved from 107.71%, 121.83%, 93.80% to 109.18%, 138.43%, 100.92% in IPBCAMS assays, WHO assays, CCDC assays, respectively.

Comparison of the specificities of the three qRT-PCR assays

To evaluate the potential cross-reactions with other human respiratory viruses, the three qRT-PCR assays were examined by using human respiratory samples as templates, which were positive for human coronaviruses (OC43, NL63, 229E, or HKU1), or Influenza viruses (A or B), or respiratory syncytial virus, or parainfluenza virus (1-4), or human metapneumovirus, or rhinovirus, or adenovirus, or bocavirus. No cross reaction was observed in all of the three qRT-PCR assays (data not shown), suggesting high specificity of the three qRT-PCR assays in detecting SARS-CoV-2.

Assay evaluation with clinical specimens

The three qRT-PCR assays were evaluated with 25 clinical specimens (including 13 throat swabs and 12 sputum) from 25 suspected COVID-19 patients. SARS-CoV-2 was detected from 92% (23/25), 60% (15/25), 100% (25/25) by the N gene assay, and from 64% (16/25), 48% (12/25), 20% (5/25) of all enrolled clinical specimens by the ORF 1b gene assay in IPBCAMS assays, WHO assays, CCDC assays, respectively (Table 4). With respect to the sputum, SARS-CoV-2 was detected from 100% (12/12), 75% (8/12), 100% (12/12) of specimens by the N gene assay, and from 100% (12/12), 75% (8/12), 41.7% (5/12) of specimens by the ORF 1b gene assay in IPBCAMS assays, WHO assays, CCDC assays, respectively. About the throat swabs, SARS-CoV-2 was detected from 84.6% (11/13), 53.8% (7/13), 100% (12/12) of specimens by the N gene assay, and from 30.8% (4/13), 30.8% (4/13), 0% (0/13) of specimens by the ORF 1b gene assay in IPBCAMS assays, WHO assays, CCDC assays, respectively. These results demonstrated that the N gene assay performed better than the corresponding ORF 1b gene assay of all the three qRT-PCR assays, the N gene assay in CCDC assays and ORF 1b gene assay in IPBCAMS assays performed better than the other assays.

Discussion

Rapid and accurate detection of SARS-CoV-2 represent a fast-growing global demand, which could be met by TaqMan real time RT-PCR (qRT-PCR). However, the current available TaqMan qRT-PCR assays for SARS-CoV-2 are varied in performance,

191 including sensitivity, specificity, reproducibility, linear detection ranges, etc. Due to
 192 that relative lower viral load in upper respiratory tract, reliable qRT-PCR assays for
 193 the detection of SARS-CoV-2 are required. We thus compared the performance of
 194 three currently wide-applied qRT-PCR assays in the detection of SARS-CoV-2.

195 Sensitivity is the primary demand in the detection of respiratory viruses (6). All of the
 196 three qRT-PCR assays could provide a LOD of 10 genomic copies per reaction with a
 197 detection range from 10^6 - 10^1 genomic copies per reaction. The Ct value at 10
 198 genomic copies per reaction in the ORF 1b gene assay of CCDC assays was higher
 199 than 35. These results suggested that most of the three qRT-PCR assays provide high
 200 sensitivity and wide linear detection range in detecting SARS-CoV-2, except a
 201 relative lower sensitivity observed in the ORF 1b gene assay of CCDC assays.

202 Specificity is also essential in the detection of SARS-CoV-2, because of common
 203 co-infections with other respiratory viruses and high host DNA background in throat
 204 swabs (7-9). We evaluated the specificity of the three qRT-PCR assays with
 205 respiratory specimens positive for other common respiratory viruses. No cross
 206 reaction was observed, demonstrating high specificity of the three qRT-PCR assays in
 207 detection of SARS-CoV-2.

208 We next evaluated the reproducibility of the three qRT-PCR assays by measuring
 209 coefficient of variation (CV) of mean Ct values in intra- and inter- assay (10). The N
 210 gene assay in IPBCAMS assays and ORF 1b gene assay in WHO assays exhibited a
 211 relative better reproducibility with lower intra- and inter- assay CVs, which were not
 212 affected by the co-existed nucleic acids of other respiratory viruses.

213 Efficiency is another key parameter of qRT-PCR, reflecting the binding efficiency of
 214 primers & probe to template and the amplification efficiency of the PCR system(11).
 215 Most of the qRT-PCR assays provided good efficiency, except an abnormal efficiency
 216 of 121.83% observed in the ORF 1b gene assay of WHO assays. An exceptionally
 217 high efficiency indicates an increased risk of false positive (12). The co-existed
 218 nucleic acids of other respiratory viruses increased the efficiency of all the three
 219 qRT-PCR assays, suggesting potential increased risk of cross-reactions between the
 220 primers & probe and background nucleic acids.

221 We finally evaluate the performance of the three qRT-PCR assays with clinical
 222 specimens from suspected SARS-CoV-2 infected patients (13). Possibly because of
 223 the lower viral load in upper respiratory tract (4), the detection rate of SARS-CoV-2
 224 was lower in throat swabs than in sputum by all of the three assays. Meanwhile, the N

gene assay performed better than the corresponding ORF 1b gene assay in all of the three qRT-PCR assays. For the N gene assay, IPBCAMS assays and CCDC assays performed better than WHO assays, both of which could detect SARS-CoV-2 from more than 90% of the suspected specimens. For the ORF1b gene assay, IPBCAMS assays performed better than WHO assays and CCDC assays, with a detection rate of 64%.

In conclusion, we performed methodological evaluations on three widely-applied qRT-PCR assays for the detection of SARS-CoV-2. Although most of the evaluated assays exhibited good sensitivity, specificity, reproducibility and wide linear detection range, performance test with clinical specimens from suspected COVID-19 patients suggested that the N gene assay in IPBCAMS assays and CCDC assays, and the ORF 1b gene assays in IPBCAMS assays were the preferred qRT-PCR assays for accurate detection of SARS-CoV-2.

Data availability

The original data will be available upon request.

Conflict of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgements

We would like to thank the clinicians who contributed to sample collection and transportation. This study was funded in part by the Project from the Ministry of Science and Technology of China (2020YFC0841200), the National Major Science & Technology Project for Control and Prevention of Major Infectious Diseases of China (2017ZX10103004), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2020HY320001), the key R&D plan of Shanxi Province (202003D31003/GZ) and the non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT310029).

Table 1. Primers and probes of the three qRT-PCR assays

Assay	Primer/probe	Sequence (5'-3')	Genomic location*	Amplicon
N gene assay	IPBCAMS assays	Forward	AACACAAGCTTTCGGCAGAC	195 bp
		Reverse	ACCTGTGTAGGTCAACCACG	
		Probe	CAGCGCTTCAGCGTTCTTCGGAATGTCGC	
	WHO assays	Forward	CACATTGGCACCCGCAATC	127 bp
		Reverse	GAGGAACGAGAAGAGGCTTG	
		Probe	ACTTCCTCAAGGAACAACATTGCCA	
	CCDC assays	Forward	GGGGAAGTTCTCTGCTAGAAT	98 bp
		Reverse	CAGACATTTTGCTCTCAAGCTG	
		Probe	TTGCTGCTGCTTGACAGATT	
	IPBCAMS assays	Forward	ACGGTGACATGGTACCACAT	215 bp
		Reverse	CTAAGTTGGCGTATACGCGT	
		Probe	TACACAATGGCAGACCTCGTCTATGC	
ORF 1b gene assay	WHO assays	Forward	GTGARATGGTCATGTGTGGCGG	99 bp
		Reverse	CARATGTTAAASACACTATTAGCATA	
		Probe	CAGGTGGAACCTCATCAGGAGATGC	
	CCDC assays	Forward	CCCTGTGGGTTTTACACTTAA	118 bp
		Reverse	ACGATTGTGCATCAGCTGA	
		Probe	CCGTCTGCGGTATGTGGAAAGGTTATGG	

Numbering according to a reference genome of SARS-CoV-2 (MN908947.3)

Table 2. Reproducibility (Coefficient of Variation, %) of the three qRT-PCR assays

Assay			Copy number of RNA transcript					
			1×10^6	1×10^5	1×10^4	1×10^3	1×10^2	1×10^1
N gene assay	IPBCAMS assays	Intra-assay	0.52*	1.33	0.37	0.46	0.20	1.25
		Inter-assay	1.06	2.45	1.49	1.32	1.37	1.45
	WHO assays	Intra-assay	1.08	1.19	1.12	0.87	0.46	5.09
		Inter-assay	7.59	2.94	2.78	6.60	0.96	3.77
	CCDC assays	Intra-assay	0.52	0.54	0.27	0.74	0.41	1.97
		Inter-assay	1.56	1.20	5.51	1.00	1.40	2.89
ORF 1b gene assay	IPBCAMS assays	Intra-assay	0.73	0.26	1.10	1.30	4.45	3.36
		Inter-assay	4.66	3.85	2.77	2.17	5.12	3.50
	WHO assays	Intra-assay	0.57	0.47	0.88	0.41	0.29	1.76
		Inter-assay	1.57	0.30	0.87	0.69	0.55	1.23
	CCDC assays	Intra-assay	1.66	0.78	0.71	0.92	2.45	6.52
		Inter-assay	0.52	0.54	0.27	0.74	0.41	1.97

The coefficient of variation was calculated by standard deviation of the Ct values of a RNA dilution divided by the mean Ct values of the same RNA dilution.

Table 3. Efficiency of the three qRT-PCR assays

	Assay	Template	Mean Ct values at quantified copy number of RNA transcript						Slope ^a	Efficiency (%) ^b
			1×10 ⁶	1×10 ⁵	1×10 ⁴	1×10 ³	1×10 ²	1×10 ¹		
N gene assay	IPBCAMS	RNA transcript ^d alone	17.63±0.09 ^c	21.99±0.29	24.08±0.09	28.25±0.13	31.00±0.06	33.73±0.25	-3.19	105.82
	assays	RNA transcript + other viruses	19.40±0.19	22.40±0.04	26.38±0.09	29.98±0.07	32.17±0.28	34.51±0.26	-3.10	110.17
	WHO assays	RNA transcript alone	18.44±0.19	22.65±0.27	26.78±0.32	29.60±0.26	32.68±0.15	33.97±1.73	-3.16	107.23
		RNA transcript + other viruses	19.51±0.15	24.83±0.36	26.59±0.29	29.62±0.54	32.62±0.70	34.19±0.51	-2.85	124.32
	CCDC assays	RNA transcript alone	17.17±0.09	20.71±0.11	23.94±0.07	27.57±0.20	30.37±0.12	33.53±0.50	-3.27	102.21
		RNA transcript + other viruses	18.93±0.16	23.79±0.20	25.66±0.23	29.58±0.52	31.92±0.16	33.81±0.87	-2.93	119.43
ORF 1b gene assay	IPBCAMS	RNA transcript alone	18.64±0.14	22.20±0.06	25.73±0.28	28.83±0.37	31.90±1.42	34.22±1.15	-3.15	107.71
	assays	RNA transcript + other viruses	19.45±0.06	22.98±0.13	25.88±0.17	29.37±0.12	32.83±0.40	34.65±2.12	-3.12	109.18
	WHO assays	RNA transcript alone	18.51±0.11	21.60±0.10	25.05±0.22	28.27±0.12	30.78±0.09	32.57±0.57	-2.89	121.83
		RNA transcript + other viruses	19.46±0.09	22.58±0.13	25.75±0.19	28.20±0.20	30.03±0.70	33.04±0.14	-2.65	138.43
	CCDC assays	RNA transcript alone	18.80±0.31	21.96±0.17	24.76±0.18	28.06±0.26	32.47±0.79	36.16±2.36	-3.48	93.80
		RNA transcript + other viruses	18.67±0.04	21.54±0.11	24.79±0.03	28.28±0.04	31.09±0.98	35.33±0.59	-3.30	100.92

^a Slope was generated by fitting of the scatter with Excel 2010.

^b Efficiency = $10^{(-1/\text{slope})} - 1$.

^c Values shown are the mean of triplicate samples ± standard deviation.

^d “RNA transcript” represents the *in vitro* transcribed RNA of the corresponding genes of SARS-CoV-2. “other viruses” represents the pooled RNA extracted from 15 human respiratory specimens by using Trizol. “RNA transcript + other viruses” represents a 1:1 (v/v) mixture of these two components.

Table 4. Evaluation of the three qRT-PCR assays with clinical specimens

Specimen ID	Specimen type	N gene assay			ORF 1b gene assay		
		IPBCAMS	WHO	CCDC	IPBCAMS	WHO	CCDC
TS98	Throat swab	35.79	NA	35.42	NA	NA	NA
TS101	Throat swab	33.48	NA	34.24	NA	NA	NA
TS103	Throat swab	NA	NA	34.68	NA	NA	NA
TS105	Throat swab	31.5	35.76	31.64	NA	NA	NA
TS108	Throat swab	33.35	NA	32.11	33.36	NA	NA
TS110	Throat swab	29.99	31.73	29.1	33.57	NA	NA
TS165	Throat swab	27.34	30.46	28.14	31.06	27.84	NA
TS168	Throat swab	NA	NA	34.97	NA	NA	NA
TS169	Throat swab	33.34	NA	34.04	NA	34.2	NA
TS187	Throat swab	34.5	39.2	33.03	NA	NA	NA
TS188	Throat swab	35.03	35.9	33.57	NA	24.07	NA
TS189	Throat swab	31.16	35.43	31.21	34.04	30.92	NA
TS190	Throat swab	32.84	34.02	32.56	NA	NA	NA
TY1	Sputum	27.35	29.44	27.6	30.98	27.33	NA
TY2	Sputum	29.38	31.26	29.06	32.32	28.72	NA
TY3	Sputum	31.85	NA	31.3	35.84	NA	NA
TY4	Sputum	22.99	25.57	22.08	27.42	24.12	35.99
TY6	Sputum	25.51	27.52	25.58	29.03	25.58	41.54
TY7	Sputum	26.9	30.21	27.4	30.05	27.3	45.26
TY8	Sputum	29.21	31.87	30.06	33.65	29.84	NA
TY9	Sputum	26.29	28.45	26.34	30.69	26.03	46.34
XT1	Sputum	25.74	27.26	25.3	29.82	26.34	45.9
XT2	Sputum	31.57	NA	30.95	34.19	NA	NA
XT3	Sputum	31.14	NA	32.02	35.02	NA	NA
XT4	Sputum	32.67	NA	31.71	34.26	NA	NA
account (%) of positive		23 (92%)	15 (60%)	25 (100%)	16 (64%)	12 (48%)	5(20%)

271

272

273

References

1. Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* doi:10.1016/S1473-3099(20)30120-1.
2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25.
3. Phan T. 2020. Novel coronavirus: From discovery to clinical diagnostics. *Infect Genet Evol* doi:10.1016/j.meegid.2020.104211:104211.
4. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. 2020. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med* doi:10.1056/NEJMc2001737.
5. Yiwei L, Yingying W, Xinming W, Yan X, Lan C, Li G, Jianguo L, Lili R, Jianwei W. 2020. Development of two TaqMan real-time reverse transcription-PCR assays for the detection of severe acute respiratory syndrome coronavirus-2. *Biosafety and Health* doi:Accepted.
6. Huang HS, Tsai CL, Chang J, Hsu TC, Lin S, Lee CC. 2018. Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. *Clin Microbiol Infect* 24:1055-1063.
7. Kim HK, Oh SH, Yun KA, Sung H, Kim MN. 2013. Comparison of Anyplex II RV16 with the xTAG respiratory viral panel and Seeplex RV15 for detection of respiratory viruses. *J Clin Microbiol* 51:1137-41.
8. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, Lu B, Zhan Q. 2020. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. *Emerg Infect Dis* 26.
9. Touzard-Romo F, Tape C, Lonks JR. 2020. Co-infection with SARS-CoV-2 and Human Metapneumovirus. *R I Med J* (2013) 103:75-76.
10. Feng ZS, Zhao L, Wang J, Qiu FZ, Zhao MC, Wang L, Duan SX, Zhang RQ, Chen C, Qi JJ, Fan T, Li GX, Ma XJ. 2018. A multiplex one-tube nested real time RT-PCR assay for simultaneous detection of respiratory syncytial virus, human rhinovirus and human metapneumovirus. *Virol J* 15:167.
11. Resa C, Magro S, Marechal P, Barranger C, Joannes M, Mischczak F, Vabret A. 2014. Development of an efficient qRT-PCR assay for quality control and cellular quantification of respiratory samples. *J Clin Virol* 60:270-5.
12. Bilgrau AE, Falgreen S, Petersen A, Kjeldsen MK, Bodker JS, Johnsen HE, Dybkaer K, Bogsted M. 2016. Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates. *BMC Bioinformatics* 17:159.

13. Zhang D, Mao H, Lou X, Pan J, Yan H, Tang H, Shu Y, Zhao Y, Cheng X, Tao H, Zhang Y, Ma X. 2018. Clinical evaluation of a panel of multiplex quantitative real-time reverse transcription polymerase chain reaction assays for the detection of 16 respiratory viruses associated with community-acquired pneumonia. Arch Virol 163:2855-2860.